A case report of breast cancer in silicone-injected breasts diagnosed by an emerging technique of contrast-enhanced mammography-guided biopsy

Contrast-enhanced mammography-guided biopsy: technique and initial outcomes

Contrast-enhanced mammography-guided biopsy (CEM-Bx), a novel technique for diagnosing suspicious enhanced lesions, was commercialized for clinical application in 2021; however, there are only a few publications documenting this technique in the existing literature. The aim of this study was to evaluate the procedural performance and preliminary outcomes of CEM-Bx performed in our hospital between from September 2021 to June 2022. We reviewed data of 12 women who underwent CEM-Bx during the study period, including their demographic and procedural characteristics, biopsy success rate, histopathological diagnosis, and average glandular dose (AGD). All women (mean age ± standard deviation: 54±6 years) showed enhanced breast lesions on CEM and underwent CEM-Bx within one week. The success rate of CEM-Bx was 100%. The vertical needle approach was used in a decubitus position (N=7, 58%), while the horizontal needle approach was used in an upright sitting position (N=5, 42%). The mean procedure time for the CEM-Bx was 17±6.3 min. The mean AGD was 14.3±12.3 mGy. Histopathologic examination revealed a malignancy rate of 66.7%. In summary, CEM-Bx is a feasible technique, with a high success rate of diagnosing contract-enhanced lesions.